Multifunctional drug delivery platform based on liposome has received much attention. With this new avenue, imaging-guided or multimodal synergic therapy can be realized, which can significantly improve the therapeutic effect and reduce toxic and side effects. Prof. Cui’s group used liposome-metal nanohybrids, which have Raman scattering activity, as the drug carrier to investigate their intracellular pathways and behaviors. In comparison with pure liposomes, the nanohybrids have similar intracellular pathways, that is, metal nanoparticles have little influence on the liposomes’ intracellular behaviors. Besides, they found that the nanohybrids exhibit excellent intracellular stability, which makes it possible to monitor their metabolic processes in cells according to their own Raman scattering signals. In short, their research demonstrates that liposome-metal nanohybrids can be designed modularly, which brings a new idea for personalized treatment based on liposomal nanohybrid carrier.
This work were published on Theranostics (IF: 8.537) as the Back cover paper. Original link: http://www.thno.org/v08p0941.pdf
